Literature DB >> 23980880

Performance of serum α-fetoprotein levels in the diagnosis of hepatocellular carcinoma in patients with a hepatic mass.

Stephen L Chan1, Frankie Mo, Philip J Johnson, Deyond Y W Siu, Michael H M Chan, Wan Y Lau, Paul B S Lai, Christopher W K Lam, Winnie Yeo, Simon C H Yu.   

Abstract

OBJECTIVES: The role of serum α-fetoprotein (AFP) measurements in the diagnosis of hepatocellular carcinoma (HCC) remains controversial. Some guidelines have advised against the use of AFP in the diagnosis of HCC. This study was conducted to evaluate the performance of AFP in the diagnosis of HCC, and to identify the optimal cut-off value of serum AFP in the diagnosis of HCC in patients with a hepatic mass.
METHODS: Patients who presented during the period from May 1997 to March 2003 with hepatic lesions, for whom paired data on serum AFP values at baseline and lesion histology were available, were reviewed. The performance of AFP in the diagnosis of HCC was determined using receiver operating characteristic curve analysis.
RESULTS: Data for a total of 805 patients were evaluated. The mean AFP value was 26,900 ng/ml (range: 0-1,965,461 ng/ml). The histological diagnosis was HCC in 557 patients. The optimal AFP cut-off value was 10 ng/ml (for sensitivity of 82.6% and specificity of 70.4%). At a cut-off level of 200 ng/ml, sensitivity, specificity, and positive and negative predictive values were 47.7%, 97.1%, 97.5% and 44.4%, respectively. The diagnostic performance of AFP remains similar in patients with chronic hepatitis B virus infection, despite a lower negative predictive value. Common aetiologies of liver lesions associated with elevated AFP include cholangiocarcinoma and neuroendocrine tumours.
CONCLUSIONS: In Asian patients with suspicious liver lesions, the cut-off AFP level of 200 ng/ml is useful to achieve a diagnosis of HCC with high specificity and reasonable sensitivity. The measurement of serum AFP should not be excluded from guidelines for the diagnosis of HCC.
© 2013 International Hepato-Pancreato-Biliary Association.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23980880      PMCID: PMC3967889          DOI: 10.1111/hpb.12146

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  33 in total

1.  Specificities of serum alpha-fetoprotein in HBsAg+ and HBsAg- patients in the diagnosis of hepatocellular carcinoma.

Authors:  H S Lee; Y H Chung; C Y Kim
Journal:  Hepatology       Date:  1991-07       Impact factor: 17.425

2.  Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions.

Authors:  K Taketa; C Sekiya; M Namiki; K Akamatsu; Y Ohta; Y Endo; K Kosaka
Journal:  Gastroenterology       Date:  1990-08       Impact factor: 22.682

3.  Plasma des-gamma-carboxyprothrombin in the early stage of hepatocellular carcinoma.

Authors:  S L Tsai; G T Huang; P M Yang; J C Sheu; J L Sung; D S Chen
Journal:  Hepatology       Date:  1990-03       Impact factor: 17.425

4.  Diffuse infiltrative hepatocellular carcinomas in a hepatitis B-endemic area: diagnostic and therapeutic impediments.

Authors:  Sun-Jung Myung; Jung-Hwan Yoon; Kang Mo Kim; Geum-Youn Gwak; Yoon Jun Kim; Ji-Won Yu; Jin Wook Chung; Hyo-Suk Lee
Journal:  Hepatogastroenterology       Date:  2006 Mar-Apr

5.  Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein.

Authors:  H Oka; A Saito; K Ito; T Kumada; S Satomura; H Kasugai; Y Osaki; T Seki; M Kudo; M Tanaka
Journal:  J Gastroenterol Hepatol       Date:  2001-12       Impact factor: 4.029

6.  The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008.

Authors:  C Verslype; E Van Cutsem; M Dicato; N Arber; J D Berlin; D Cunningham; A De Gramont; E Diaz-Rubio; M Ducreux; T Gruenberger; D Haller; K Haustermans; P Hoff; D Kerr; R Labianca; M Moore; B Nordlinger; A Ohtsu; P Rougier; W Scheithauer; H-J Schmoll; A Sobrero; J Tabernero; C van de Velde
Journal:  Ann Oncol       Date:  2009-06       Impact factor: 32.976

Review 7.  Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative.

Authors:  Patrick M Bossuyt; Johannes B Reitsma; David E Bruns; Constantine A Gatsonis; Paul P Glasziou; Les M Irwig; Jeroen G Lijmer; David Moher; Drummond Rennie; Henrica C W de Vet
Journal:  BMJ       Date:  2003-01-04

8.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

9.  Structures of disease-specific serum alpha-fetoprotein isoforms.

Authors:  P J Johnson; T C Poon; N M Hjelm; C S Ho; C Blake; S K Ho
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

10.  Frequency of raised alpha-fetoprotein level among Chinese patients with hepatocellular carcinoma related to hepatitis B and C.

Authors:  J F Tsai; W Y Chang; J E Jeng; M S Ho; Z Y Lin; J H Tsai
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

View more
  23 in total

Review 1.  Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma.

Authors:  Pei-Pei Song; Ju-Feng Xia; Yoshinori Inagaki; Kiyoshi Hasegawa; Yoshihiro Sakamoto; Norihiro Kokudo; Wei Tang
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

2.  Prognostic impact of toll-like receptors 2 and 4 expression on monocytes in Egyptian patients with hepatocellular carcinoma.

Authors:  Asmaa M Zahran; Zeinab Albadry M Zahran; Omnia El-Badawy; Mona H Abdel-Rahim; Wageeh A M Ali; Amal Rayan; Muhammad Abbas El-Masry; Mohamed A A Abozaid; Helal F Hetta
Journal:  Immunol Res       Date:  2019-06       Impact factor: 2.829

3.  The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma.

Authors:  Rathasapa Patarat; Shoji Riku; Pattapon Kunadirek; Natthaya Chuaypen; Pisit Tangkijvanich; Apiwat Mutirangura; Charoenchai Puttipanyalears
Journal:  Sci Rep       Date:  2021-07-21       Impact factor: 4.379

Review 4.  Hepatocellular carcinoma: A comprehensive review.

Authors:  Lisa P Waller; Vrushak Deshpande; Nikolaos Pyrsopoulos
Journal:  World J Hepatol       Date:  2015-11-18

5.  Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

Authors:  Agostino Colli; Tin Nadarevic; Damir Miletic; Vanja Giljaca; Mirella Fraquelli; Davor Štimac; Giovanni Casazza
Journal:  Cochrane Database Syst Rev       Date:  2021-04-15

6.  Feasibility of α-fetoprotein as a diagnostic tool for hepatocellular carcinoma in Korea.

Authors:  Dae Geon Ahn; Hyung Joon Kim; Hyun Kang; Hyun Woong Lee; Si Hyun Bae; Joon Hyoek Lee; Yong Han Paik; June Sung Lee
Journal:  Korean J Intern Med       Date:  2015-12-28       Impact factor: 2.884

7.  CD133 expression and α-fetoprotein levels define novel prognostic subtypes of HBV-associated hepatocellular carcinoma: A long-term follow-up analysis.

Authors:  Xiao-Meng Dai; Sheng-Li Yang; Xiu-Mei Zheng; George G Chen; Jing Chen; Tao Zhang
Journal:  Oncol Lett       Date:  2017-12-28       Impact factor: 2.967

Review 8.  Circulating biomarkers for early detection of hepatocellular carcinoma.

Authors:  Boris J B Beudeker; Andre Boonstra
Journal:  Therap Adv Gastroenterol       Date:  2020-06-29       Impact factor: 4.409

9.  Development of Serum DHCR24 Antibody as a Marker for Hepatocellular Carcinoma: The End of the Beginning.

Authors:  Stephen L Chan; Anthony W H Chan
Journal:  EBioMedicine       Date:  2015-05-22       Impact factor: 8.143

10.  Hepatocellular carcinoma in Ghana: a retrospective analysis of a tertiary hospital data.

Authors:  Kenneth Tachi; Adwoa Agyei-Nkansah; Timothy Archampong
Journal:  Pan Afr Med J       Date:  2020-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.